Eli Lilly and Roche ask CMS not to be lumped in with Aduhelm’s restrictive judgment

With CMS closing its public comment period for its draft decision to limit coverage of Biogen’s Aduhelm last week, two Big Pharma companies developing similar Alzheimer’s drugs got in their comments just before Thursday’s deadline.